Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
COL6A2 Double Nickase Plasmid (h): sc-403209-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- COL6A2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- COL6A2 Double Nickase Plasmid (h) and COL6A2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting COL6A2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: COL6A2 Antibody (B-7): sc-374566
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
COL6A2 Double Nickase Plasmid (h) | sc-403209-NIC | 20 µg | $410.00 | |||
COL6A2 Double Nickase Plasmid (h2) | sc-403209-NIC-2 | 20 µg | $410.00 |
COL6A2 encodes the α2 chain of type VI collagen, a key extracellular matrix component that assembles with COL6A1 and COL6A3 into microfibrillar networks surrounding many cell types. This collagen VI matrix supports tissue architecture, cell–matrix adhesion, and mechanotransduction, shaping processes such as myogenesis, fibroblast behavior, and extracellular matrix remodeling. COL6A2 function interfaces with integrin and dystroglycan-associated signaling and influences matrix-dependent survival and stress responses. Pathogenic COL6A2 variants are linked to collagen VI–related myopathies, including Ullrich congenital muscular dystrophy and Bethlem myopathy, making it a frequent target in studies of muscle integrity and extracellular matrix dysfunction.
COL6A2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the COL6A2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within COL6A2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt COL6A2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of COL6A2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.